Publications

ContiVir is based on a strong scientific foundation from many years of research at the Bioprocess Engineering Group led by Prof. Dr.-Ing. Udo Reichl of the Max-Planck-Institute for Dynamics of Complex Technical Systems in Magdeburg, Germany.

​

Our technologies are grounded on both patents and scientific publications in peer-reviewed journals.

​

We also list selected talks and posters in several respected scientific conferences around the world.

Our purification technology can achieve >98% yield for 7 different AAV serotypes and recombinant variants using a single standardized setup:

Marichal-Gallardo P, et al. Single-use purification of adeno-associated viral gene transfer vectors by membrane-based steric exclusion chromatography. 2019, submitted.

​

Our tubular bioreactor could continually produce influenza A virus for over 3 weeks and is the only production system that avoids the accumulation of defective interfering particles:

Tapia F, et al. Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the “von Magnus effect.”

PLoS ONE 2019;14:e0224317–1.

​

Our purification technology achieves 20–40% more yield (>98%) for influenza A virus compared to existing purification methods by using a disposable device:

Marichal-Gallardo P, et al. Steric exclusion chromatography for purification of cell culture-derived influenza A virus using regenerated cellulose membranes and polyethylene glycol.

J Chromatogr A 2017;1483:110–119.

​

We show stable continuous production of MVA virus for over 3 weeks using a cascade of two stirred tanks:

Tapia F, et al. Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.

PLoS ONE 2017;12:e0182553–17.

​

Review article with the latest trends in continuous cultivations of suspension cells for the production of virus particles:

Tapia F, et al. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.

Appl Microbiol Biotechnol 2016;100:2121–2132.

​

​

​

Conference Talks

​

Our purification technology is the only single-use chromatography method which purifies a wide variety of viruses (influenza virus, yellow fever virus, Vaccinia virus, AAV) with typical yields above 95% at high flow rate using a one-size-fits-all setup:

Marichal-Gallardo P, et al.

A single-use chromatographic purification platform for viral gene transfer vectors & viral vaccines.

Advancing Manufacture of Cell and Gene Therapies VI

Coronado, CA, USA. January 2019

​

Our purification technology yielded more than 100 000 doses of yellow fever vaccine in less than 3 hours without product losses and with impurity levels below the regulatory requirements for human vaccines:

Marichal-Gallardo P, et al.

Purifying viruses with a sheet of paper: Single-use steric exclusion chromatography as a capture platform for vaccine candidates.

Vaccine Technology VII

Mont Tremblant, Canada. June 2018

​

Our production technology has 20x smaller volumes is the only bioreactor system that enables stable virus production over weeks and without accumulation of mutant viruses.

Tapia, F, et al.

Multi-stage bioreactor concepts for continuous virus vaccine production.

Continuous Biomanufacturing: Achievements and Challenges for Commercial Implementation

Oxford, UK, 2018

​

​

WO2017190790A1, Tapia F, et al. Plug flow tubular bioreactor, system containing the same and method for production of virus. (Pending)

​

WO2017076553A1, Wolff MW, et al. Method for the separation of virus compositions including depletion and purification thereof. (Pending)

​

​

​